CEGEDIM SA (CGM.PA) Stock Fundamental Analysis
EPA:CGM - FR0000053506 - Common Stock
10.4 EUR
-0.2 (-1.89%)
Overall CGM gets a fundamental rating of 2 out of 10. We evaluated CGM against 10 industry peers in the Health Care Technology industry. Both the profitability and financial health of CGM have multiple concerns. CGM is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CGM has reported negative net income.
In the past year CGM had a positive cash flow from operations.
In multiple years CGM reported negative net income over the last 5 years.
Each year in the past 5 years CGM had a positive operating cash flow.
1.2 Ratios
CGM has a worse Return On Assets (-1.49%) than 60.00% of its industry peers.
CGM's Return On Equity of -5.56% is on the low side compared to the rest of the industry. CGM is outperformed by 60.00% of its industry peers.
The Return On Invested Capital of CGM (4.46%) is worse than 60.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CGM is significantly below the industry average of 9.32%.
The last Return On Invested Capital (4.46%) for CGM is above the 3 year average (2.87%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.49% | ||
| ROE | -5.56% | ||
| ROIC | 4.46% |
ROA(3y)-0.25%
ROA(5y)0.74%
ROE(3y)-1.16%
ROE(5y)2.61%
ROIC(3y)2.87%
ROIC(5y)3.89%
1.3 Margins
CGM has a Operating Margin of 5.75%. This is in the lower half of the industry: CGM underperforms 60.00% of its industry peers.
In the last couple of years the Operating Margin of CGM has declined.
With a Gross Margin value of 20.07%, CGM is not doing good in the industry: 90.00% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of CGM has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.75% | ||
| PM (TTM) | N/A | ||
| GM | 20.07% |
OM growth 3Y-6.64%
OM growth 5Y-3.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.96%
GM growth 5Y-1.7%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CGM is still creating some value.
Compared to 1 year ago, CGM has more shares outstanding
Compared to 5 years ago, CGM has less shares outstanding
CGM has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.27, we must say that CGM is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.27, CGM is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
CGM has a debt to FCF ratio of 27.31. This is a negative value and a sign of low solvency as CGM would need 27.31 years to pay back of all of its debts.
CGM has a Debt to FCF ratio (27.31) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.14 is on the high side and indicates that CGM has dependencies on debt financing.
CGM has a Debt to Equity ratio of 1.14. This is amonst the worse of the industry: CGM underperforms 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | 27.31 | ||
| Altman-Z | 1.27 |
ROIC/WACC1.1
WACC4.05%
2.3 Liquidity
A Current Ratio of 0.99 indicates that CGM may have some problems paying its short term obligations.
With a Current ratio value of 0.99, CGM is not doing good in the industry: 70.00% of the companies in the same industry are doing better.
CGM has a Quick Ratio of 0.99. This is a bad value and indicates that CGM is not financially healthy enough and could expect problems in meeting its short term obligations.
CGM's Quick ratio of 0.97 is on the low side compared to the rest of the industry. CGM is outperformed by 70.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.97 |
3. Growth
3.1 Past
CGM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -97.97%.
CGM shows a small growth in Revenue. In the last year, the Revenue has grown by 6.25%.
The Revenue has been growing slightly by 5.38% on average over the past years.
EPS 1Y (TTM)-97.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1194.13%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y7.65%
Revenue growth 5Y5.38%
Sales Q2Q%6.51%
3.2 Future
The Earnings Per Share is expected to grow by 21.86% on average over the next years. This is a very strong growth
Based on estimates for the next years, CGM will show a small growth in Revenue. The Revenue will grow by 3.41% on average per year.
EPS Next Y-1.77%
EPS Next 2Y20.1%
EPS Next 3Y21.86%
EPS Next 5YN/A
Revenue Next Year1.46%
Revenue Next 2Y2.88%
Revenue Next 3Y3.41%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CGM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 9.28 indicates a reasonable valuation of CGM.
Based on the Price/Forward Earnings ratio, CGM is valued cheaply inside the industry as 90.00% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.48, CGM is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.28 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CGM indicates a rather cheap valuation: CGM is cheaper than 100.00% of the companies listed in the same industry.
CGM's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CGM is cheaper than 90.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.29 | ||
| EV/EBITDA | 3.23 |
4.3 Compensation for Growth
CGM's earnings are expected to grow with 21.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.1%
EPS Next 3Y21.86%
5. Dividend
5.1 Amount
CGM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:CGM (9/3/2025, 7:00:00 PM)
10.4
-0.2 (-1.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners17.29%
Inst Owner ChangeN/A
Ins Owners57.12%
Ins Owner ChangeN/A
Market Cap146.64M
Analysts48.89
Price Target12.92 (24.23%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.56%
PT rev (3m)-7.32%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-24.49%
EPS NY rev (3m)-24.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.28 | ||
| P/S | 0.22 | ||
| P/FCF | 12.29 | ||
| P/OCF | 1.44 | ||
| P/B | 0.55 | ||
| P/tB | N/A | ||
| EV/EBITDA | 3.23 |
EPS(TTM)-1.07
EYN/A
EPS(NY)1.12
Fwd EY10.78%
FCF(TTM)0.85
FCFY8.14%
OCF(TTM)7.22
OCFY69.45%
SpS46.42
BVpS18.75
TBVpS-11.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.49% | ||
| ROE | -5.56% | ||
| ROCE | 6.06% | ||
| ROIC | 4.46% | ||
| ROICexc | 4.84% | ||
| ROICexgc | 19.22% | ||
| OM | 5.75% | ||
| PM (TTM) | N/A | ||
| GM | 20.07% | ||
| FCFM | 1.82% |
ROA(3y)-0.25%
ROA(5y)0.74%
ROE(3y)-1.16%
ROE(5y)2.61%
ROIC(3y)2.87%
ROIC(5y)3.89%
ROICexc(3y)3.13%
ROICexc(5y)4.15%
ROICexgc(3y)11.62%
ROICexgc(5y)15.26%
ROCE(3y)3.91%
ROCE(5y)5.29%
ROICexcg growth 3Y0.21%
ROICexcg growth 5Y-3.19%
ROICexc growth 3Y-3.24%
ROICexc growth 5Y-2.52%
OM growth 3Y-6.64%
OM growth 5Y-3.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.96%
GM growth 5Y-1.7%
F-Score3
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | 27.31 | ||
| Debt/EBITDA | 2.3 | ||
| Cap/Depr | 96.22% | ||
| Cap/Sales | 13.74% | ||
| Interest Coverage | 4.24 | ||
| Cash Conversion | 77.7% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.97 | ||
| Altman-Z | 1.27 |
F-Score3
WACC4.05%
ROIC/WACC1.1
Cap/Depr(3y)92.57%
Cap/Depr(5y)94.88%
Cap/Sales(3y)13.24%
Cap/Sales(5y)13.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1194.13%
EPS Next Y-1.77%
EPS Next 2Y20.1%
EPS Next 3Y21.86%
EPS Next 5YN/A
Revenue 1Y (TTM)6.25%
Revenue growth 3Y7.65%
Revenue growth 5Y5.38%
Sales Q2Q%6.51%
Revenue Next Year1.46%
Revenue Next 2Y2.88%
Revenue Next 3Y3.41%
Revenue Next 5YN/A
EBIT growth 1Y79.81%
EBIT growth 3Y0.5%
EBIT growth 5Y1.66%
EBIT Next Year278.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-46.81%
FCF growth 3Y-27.43%
FCF growth 5YN/A
OCF growth 1Y4.01%
OCF growth 3Y2%
OCF growth 5Y28.33%